Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to GABA(-) and GABA(+) ligand with K i s of 5.15 and 6.11 nM, respectivelyForm:SolidIC50& Target:Ki: 5.15±0.39 nM (GABA(-) ligand), 6.11±0.26 nM
Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to GABA(-) and GABA(+) ligand with K i s of 5.15 and 6.11 nM, respectivelyForm:SolidIC50& Target:Ki: 5.15±0.39 nM (GABA(-) ligand), 6.11±0.26 nM
Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to GABA(-) and GABA(+) ligand with K i s of 5.15 and 6.11 nM, respectivelyForm:SolidIC50& Target:Ki: 5.15±0.39 nM (GABA(-) ligand), 6.11±0.26 nM
Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to GABA(-) and GABA(+) ligand with K i s of 5.15 and 6.11 nM, respectivelyForm:SolidIC50& Target:Ki: 5.15±0.39 nM (GABA(-) ligand), 6.11±0.26 nM
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing
Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.In VivoWhen the animals are pretreated with high doses of Rilmazafone hydrochloride (450191-S 200 or 600 mg/kg for 5 or 3 days, respectively) to induce hepatic drug-metabolizing